Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
29 hedge funds and large institutions have $48.9M invested in Trillium Therapeutics Inc. in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 8 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
9% more capital invested
Capital invested by funds: $44.8M → $48.9M (+$4.11M)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
12% less funds holding
Funds holding: 33 → 29 (-4)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$2.07M |
| 2 |
Millennium Management
New York
|
+$974K |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$687K |
| 4 |
Renaissance Technologies
New York
|
+$335K |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$174K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.22M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$847K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$490K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$292K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$204K |
TRIL Hedge Fund Activity: Q4 2015 in Review
29 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q4 2015, worth a combined $48.9M — up 9.2% from $44.8M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of TRIL and 4 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $2.07M. The largest seller was Fidelity Investments, exiting entirely with an estimated $1.22M sold.
- 29 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q4 2015, down from 33 in Q3 2015.
- Funds reported $48.9M of Trillium Therapeutics Inc. stock for Q4 2015, up 9.2% quarter-over-quarter.
- 4 funds opened new Trillium Therapeutics Inc. positions in Q4 2015 and 8 closed out, a net change of -4 holders.
- The largest Trillium Therapeutics Inc. buyer in Q4 2015 was Baker Bros. Advisors, an estimated $2.07M added.
- The largest Trillium Therapeutics Inc. seller in Q4 2015 was Fidelity Investments, an estimated $1.22M sold.
Based on aggregated 13F filings for Q4 2015.